Reuters Health News Summary

The German company's Monsanto unit had been found liable in November by a Cole County, Missouri, jury to Valorie Gunther of New York, Jimmy Draeger of Missouri and Daniel Anderson of California, who blamed their non-Hodgkin's lymphoma on their exposure to Roundup. US FDA allows expanded use of J&J, Bristol Myers cell therapies The U.S. Food and Drug Administration has allowed cell therapies of Johnson & Johnson and Bristol Myers Squibb to be used for treating patients in the earlier stages of a type of blood cancer, the companies said on Friday.

Following is a summary of current health news briefs.

U.S. FDA approves expanded use of J&J's cancer cell therapy

The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson and Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.

CDC issues health alert for bird flu infection in US

The U.S. CDC on Friday issued a health alert to inform clinicians, state health departments and the public of a case of avian influenza in a person who had contact with dairy cows presumed to be infected with the virus. The farm worker from Texas was reported to be infected on April 1, making it the second case of the H5N1 strain of avian influenza, commonly known as bird flu, identified in a person in the United States.

US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors

The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.

The drug, sold under the brand name Enhertu, originally won U.S. approval in late 2019 as a third-line treatment for HER-2-positive breast cancer patients, and the fresh approval opens the treatment across multiple HER2-expressing solid tumors.

AstraZeneca's Imfinzi improves survival in late-stage lung cancer trial

AstraZeneca said on Friday its blockbuster cancer drug Imfinzi helped improve survival in patients in the early stages of an aggressive type of lung cancer, making it the first such immunotherapy to meet two key trial goals. In a late-stage trial, the drug demonstrated "statistically significant and clinically meaningful improvement" in both overall survival and slowing the progression of the cancer in patients for whom the disease had not worsened following chemoradiotherapy, according to the Anglo-Swedish drugmaker.

Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies

Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics. The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. Long-term data of the drug reinforced the findings that were seen in previous short-term studies, the company said.

J&J boosts heart device business in $13.1 billion Shockwave deal

Johnson & Johnson on Friday agreed to buy Shockwave Medical in a deal valued at $13.1 billion including debt, as it builds its cardiac-health-centric medical devices business to help drive growth. J&J has offered $335 per share in cash that values the equity portion at $12.5 billion, based on Reuters' calculations. The offer also represents a 17% premium to the stock's closing price in late March, when the Wall Street Journal reported J&J's interest in Shockwave, whose shares were currently trading at $326.82.

Boehringer to lay off salespeople as Humira biosimilar sales lag

Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie's blockbuster arthritis treatment Humira. The German drugmaker said it planned to reduce its customer-facing teams in favor of a hybrid in-person and virtual sales model by June 30, in large part because pharmacy benefit managers (PBMs) had kept branded Humira on their lists of medicines for reimbursement.

Judge slashes Bayer $1.56 billion Roundup verdict to $611 million

A Missouri judge slashed a $1.56 billion verdict against Bayer to $611 million for three people who claimed its Roundup weed killer caused their cancer, by reducing punitive damages. Bayer said on Friday it is appealing. The German company's Monsanto unit had been found liable in November by a Cole County, Missouri, jury to Valorie Gunther of New York, Jimmy Draeger of Missouri and Daniel Anderson of California, who blamed their non-Hodgkin's lymphoma on their exposure to Roundup.

US FDA allows expanded use of J&J, Bristol Myers cell therapies

The U.S. Food and Drug Administration has allowed cell therapies of Johnson & Johnson and Bristol Myers Squibb to be used for treating patients in the earlier stages of a type of blood cancer, the companies said on Friday. Both J&J and Bristol Myers' therapies helped extend the time that patients lived without disease progression in late stage studies — more than when patients received 'standard of care' treatments, the companies said in separate statements.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)